INTRODUCTION
Traditional approaches to the treatment of type 2 diabetes mellitus (T2DM) have focused on improving insulin secretion and insulin sensitivity with the aim of lowering blood glucose levels to meet glycosylated hemoglobin (HbA 1c ) targets while avoiding hypoglycemia [1, 2] . However, evidence suggests that only around half of patients achieve an HbA 1c target of less than 7% [3] .
Recent studies report limited benefits of intensive glucose lowering on mortality and cardiovascular outcomes in patients with T2DM [4] [5] [6] [7] [8] . Therefore, future management strategies should address features beyond glucose control [9, 10] .
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a promising new class of compounds in development that offer an alternative mechanism for control of hyperglycemia in T2DM by reducing glucose reabsorption in the kidney and thereby increasing urinary glucose excretion (UGE) [11] [12] [13] . Clinical studies of SGLT2 inhibitors have demonstrated glucose lowering efficacy, a favorable safety profile, and beneficial effects on weight, blood pressure, and other metabolic parameters [14] [15] [16] [17] [18] [19] .
Empagliflozin is an SGLT2 inhibitor in development as a treatment for T2DM. In in vitro studies, empagliflozin exhibited highly potent inhibition of SGLT2 (half maximal inhibitory concentration [IC 50 ] of 3.1 nM [pIC 50 (SE) 8.5 (0.02) nM]), with a [2,500-fold selectivity for SGLT2 over SGLT1 [20] . Single oral doses of empagliflozin were well tolerated in healthy volunteers resulting in dose-dependent UGE without inducing hypoglycemia [21] . The objective of this multiple ascending dose study, the first study of empagliflozin in patients with T2DM, was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in this patient population.
Study Design
This was a multiple rising dose, randomized, double-blind trial with within-group placebo control. Patients were randomized upon admission to the trial center to one of four doses of empagliflozin (2.5, 10, 25, and 100 mg), which were tested sequentially in ascending order of dose. Within every dose group, patients were randomized 3:1 to receive active drug or placebo. Treatment allocation was carried out according to a randomized list of patient and medication numbers. Within each dose group, patients were randomized to receive placebo or active drug and patients and investigators were double blinded until the study had completed. Patients and investigators were aware of the dosing stage (but not if patients were receiving placebo).
Patients received a single dose on day 1 and once-daily dosing on days 3-9. The dosing on day 2 was skipped to allow estimation of the terminal elimination half-life after a single dose to compare with the steady state half-life. Study drug was administered at the same time every day with 240 mL of water. Patients were fasted overnight for 10 h on days -2, -1, 1, 8, and 9.
An end-of-study examination was carried out in the 1-week post-treatment period (days [15] [16] [17] [18] [19] [20] [21] ). An oral glucose tolerance test (OGTT; administration of 75 g glucose solution after overnight fasting) was performed on days -1, 1, and 9.
Subjects
The trial was conducted at the Profil Institute 
Evaluations
The primary endpoint was safety and tolerability. Safety parameters, including adverse events (AEs), electrocardiogram (ECG), vital signs, physical examination, and laboratory parameters in blood and urine samples, were measured throughout the study. Meals and fluid intake were standardized during the in-house period of the study (from day -2 to day 9). Secondary endpoints were pharmacokinetic and pharmacodynamic parameters. Pharmacokinetic endpoints included mean plasma concentration time profiles of empagliflozin, maximum concentration of analyte in plasma (C max ), time to reach peak levels (t max ), terminal elimination half-life (t 1/2 ), apparent terminal rate constant (kz), area under the plasma concentration-time curve (AUC), renal clearance (CL R ) and the fraction of the dose that was excreted unchanged in urine (fe).
Pharmacodynamic measurements included UGE, 8-point weighted mean daily glucose (MDG), and fasting plasma glucose (FPG). Samples for the determination of analyte plasma concentrations were drawn before drug administration on days -2, -1, 1, 2, 3, and 5-9, at time points up to 48 h after dosing on day 1, and up to 72 h after dosing on day 9. On days -2, -1, 1, 8, and 9 all urine voided over a period of 24 h (48 h for day 1 and 72 h for day 9) was collected for UGE measurements. Urine samples 
RESULTS

Patient Disposition
Seventy-four patients were screened and 48 (39 white males, 8 white females, 1 black female)
were randomized (12 to each dose group, with 9 patients randomized to receive empagliflozin treatment and 3 to placebo). All randomized patients received at least 1 dose of study drug;
46 patients received 8 doses of empagliflozin or placebo over 8 days, 1 patient received 6 doses of placebo over 6 days, and 1 patient received 2 doses of empagliflozin over 2 days. Forty-six patients completed the study, with 2 patients discontinuing treatment prematurely due to adverse events. Baseline characteristics are summarized in Table 1 .
Safety and Tolerability
In total, 24 (50.0%) patients experienced AEs during the treatment period. No AEs were reported in the 1-week post-treatment period.
The frequency of AEs was 52.8% in patients receiving empagliflozin treatment and 41.7%
with placebo. The most frequently reported AE was headache, reported by 4 patients (8.3%) during the treatment period, occurring in 0-2 (Table 5) .
Pharmacokinetics
Empagliflozin was rapidly absorbed after oral administration, reaching peak levels between 1.5 (2) 140 (2) 141 (1) 140 (1) 139 (2) 139 (2) 138 (2) 139 ( 179 (16) 173 (7) 181 (9) 175 (11) 173 (27) 171 (25) 185 (15) 174 (13) 181 (9) 174 (11) HDL-cholesterol (mg/dL)
43 (22) 31 (16) 15 (21) 16 (18) 46 (29) 31 (18) 47 (12) 41 (17) 42 (19) 37 (18) Triglycerides (mg/dL) 177 (121) Fig. 1 Mean plasma concentration-time profiles of empagliflozin after multiple oral doses of 2.5-100 mg (semi-log scale).
Data from the pharmacokinetic analysis set (n = 36) SD standard deviation a n = 11 at 166 and 184 h b n = 7 at 166 h (CL R, 0-48h ) was 15.0-29.1 mL/min and at steady state on day 9 (CL R,s,ss ) was 23.5-34.4 mL/min (Table 6 ). Overall, steady state parameters were similar to single dose parameters, suggesting linear pharmacokinetics with respect to time ( Table 6 ).
Pharmacodynamics
At all doses, oral administration of empagliflozin increased UGE above the level of placebo, with both the amount and rate of glucose excretion increasing with dose. After a single dose under OGTT conditions (day 1; Fig. 2 ), the amount of glucose excreted in the urine over 24 h (Ae 0-24 ) was 46.3 g with 2.5 mg empagliflozin compared with 5.84 g with placebo. There was more than a twofold increase in UGE with the fourfold increase in dose from 2.5 to 10 mg, in contrast with about a 1.2-fold increase in UGE with the fourfold dose increase in dose from 25 to 100 mg.
Glucose excretion seemed to plateau after the 10 mg dose, with total cumulative amounts excreted ranging from 77.9 mg to 89.8 g with 10 to 100 mg empagliflozin after a single dose.
Similar results were observed after multiple doses with or without OGTT (days 9 and 8, respectively; Fig. 2 ). Empagliflozin inhibited reabsorption of 39%, 46%, 58%, and 64% of filtered glucose with 2.5, 10, 25, and 100 mg once-daily doses, respectively (Fig. 3) . The mean decrease in FPG from baseline (day -1) to day 9 (based on least squares means) ranged from 17.2% to 25.8% with empagliflozin, compared with 12.7% with placebo. The overall decline in FPG was 4.6-13.2% greater with empagliflozin than with placebo (Fig. 4) . The decrease in FPG from baseline was significantly different compared to placebo with the 10 mg dose (Fig. 4) . A respective decrease in plasma glucose levels was also observed following OGTT immediately after the first dose. The mean decrease in MDG from Table 6 Summary of pharmacokinetic parameters of empagliflozin after oral administration of single and multiple doses of empagliflozin (days 1 and 9) Table 5 ). The decrease in MDG from baseline was significantly different compared to placebo with the 2.5 and 10 mg doses (Table 7) . After OGTT, reductions in plasma glucose levels in empagliflozin groups were greater than in the placebo group. Mean AUEC [1] [2] [3] [4] [5] values decreased approximately 22.9-27.5% from baseline with empagliflozin, compared with 14.2% with placebo (Table 8) . Serum insulin levels did not change to a relevant degree (data not shown).
DISCUSSION
This randomized, double-blind, placebo-controlled trial examined the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin (2.5, 10, 25, and 100 mg) administered to adult patients with T2DM. Analysis of safety data showed that empagliflozin was well tolerated in patients with T2DM. There were no serious AEs associated with drug treatment and the frequency of AEs with empagliflozin treatment was similar to placebo. Importantly, plasma glucose was lowered in the absence of non-OGTT-related episodes of hypoglycemia. Furthermore, there were no safety findings of concern, with no clinically significant changes observed in creatinine clearance, urine volume or micturition frequency following empagliflozin administration under Data from the treated analysis set (n = 48). Weighted MDG, weighted mean daily glucose estimated by dividing the area under the 24-h glucose curve by 24 h for each patient on each day SD standard deviation a n = 11 on day 8 b n = 8 on day 8 ranged from 30.6 to 78.6 g/day [21] . Reports of UGE following administration of the SGLT2 inhibitor dapagliflozin were 60 g/day in a study of 2.5-100 mg dapagliflozin doses administered to healthy subjects [22] and 52-85 g/day with 2.5-50 mg doses of dapagliflozin administered to patients with T2DM [23] . Canagliflozin treatment resulted in maximal UGE of 70 g/day with doses of 200-800 mg qd in healthy subjects [24] . Ipragliflozin dose dependently increased UGE up to a maximum of approximately 59 g/day following multiple doses of 5-600 mg in healthy volunteers and 90 g/day following multiple doses of 300 mg in patients with T2DM [25, 26] . However, cross-study pharmacodynamic comparisons are difficult, as the efficacy of SGLT2 inhibitors may depend on overall glycemic status [27] .
In this study, empagliflozin inhibited reabsorption of renally filtered glucose by approximately 39-64% under steady state conditions. Again, these data are comparable Data from the treated analysis set (n = 48) AUEC 1-5 area under the 24-h glucose concentration-time curve 1-5h, SD standard deviation a n = 11 on day 9 b n = 8 on day 9
with the results of the single rising dose study [21] , reporting levels of inhibition of approximately 12-56% with single empagliflozin doses administered to healthy volunteers over the same dose range.
The increased UGE resulted in a substantial decrease in both FPG and PPG and therefore also in MDG versus placebo at all doses tested. Whereas UGE was similar after single and multiple dosing, the plasma glucose lowering effect of empagliflozin occurred immediately after the first dose and increased with treatment duration. Importantly, empagliflozin exhibited a sustained blood glucose lowering effect on day 10 (i.e., 1 day after the intake of the last dose). The FPG levels in the empagliflozin groups were at least 14% lower than on day 1, which was twice as high as the reduction observed with placebo.
This supports the suitability of once-daily dosing with empagliflozin. 
